Zucara Therapeutics Announces Additional Funding From Jdrf To Support Zt-01 Phase 2 Study
Round Type
Funding Round
TorontoBiotechnologyHealth CareTherapeuticsInvestors
Description
Zucara Therapeutics Inc., ("Zucara" or the "Company") a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced additional funding from JDRF, the leading global Type 1 diabetes ("T1D") research and advocacy organization. Through its Industry Discovery & Development Partnerships ("IDDP") program, JDRF will provide US$2 million in funding to support Zucara's planned Phase 2a study of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes mellitus ("ZONE"). Zucara expects to begin patient dosing in the third quarter of 2023.
Quick answer
Zucara Therapeutics raised an undisclosed amount in a Funding Round round, dated June 15, 2023. Investors: Industry Discovery & Development Partnerships and Jdrf. Zucara Therapeutics is based in Toronto, Ontario, Canada.
- How much did Zucara Therapeutics raise?
- Zucara Therapeutics raised an undisclosed amount in a Funding Round round on June 15, 2023.
- Who invested in Zucara Therapeutics?
- Industry Discovery & Development Partnerships and Jdrf are named as investors in this round.
- What does Zucara Therapeutics do?
- Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes.
- Where is Zucara Therapeutics based and how big is it?
- Zucara Therapeutics is based in Toronto, Ontario, Canada. Fundz records about 10 employees.
- Who are the decision-makers at Zucara Therapeutics?
- Fundz holds 1 contact at Zucara Therapeutics, including the Co Founder & Chief Scientific Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Zucara Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- KayoThera, Inc. raised an undisclosed amount (Series A) on July 19, 2023.
- SURGE Therapeutics raised $32M (Series B) on July 19, 2023.
- Renibus Therapeutics raised $47M (Funding Round) on July 18, 2023.
- Tenpoint Therapeutics raised $70M (Series A) on July 12, 2023.
- Smartlens raised $6.1M (Series A) on July 11, 2023.
- TolerogenixX raised $13M (Series A) on July 6, 2023.
Who to call at Zucara Therapeutics, and when
A new round usually means Zucara Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Zucara Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Zucara Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Zucara Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Zucara Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Zucara Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.